The latest price target for Disc Medicine (NASDAQ:IRON) was reported by Stifel on December 10, 2024. The analyst firm set a price target for $90.00 expecting IRON to rise to within 12 months (a possible 39.53% upside). 29 analyst firms have reported ratings in the last year.

The latest analyst rating for Disc Medicine (NASDAQ:IRON) was provided by Stifel, and Disc Medicine maintained their buy rating.

The last upgrade for Disc Medicine Inc happened on June 12, 2023 when Raymond James raised their price target to $75. Raymond James previously had an outperform for Disc Medicine Inc.

The last downgrade for Disc Medicine Inc happened on April 1, 2024 when Raymond James changed their price target from $75 to $40 for Disc Medicine Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Disc Medicine, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Disc Medicine was filed on December 10, 2024 so you should expect the next rating to be made available sometime around December 10, 2025.

While ratings are subjective and will change, the latest Disc Medicine (IRON) rating was a maintained with a price target of $79.00 to $90.00. The current price Disc Medicine (IRON) is trading at is $64.50, which is out of the analyst’s predicted range.